Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With: mrna

  • Can Maternal COVID-19 Vaccination Protect Newborns?

    In this case control study, 537 case infants younger than 6 months of age who were admitted to the hospital with COVID-19 were compared to 512 control infants who were hospitalized for other reasons; 16% of the case infants and 29% of the control infants had been born to mothers who had been fully vaccinated against COVID-19 during the pregnancy. The effectiveness of maternal vaccination against infant hospitalization for COVID-19 was 52% overall, 80% during the Delta variant period, and 38% during the Omicron variant period. Effectiveness increased when the vaccine was received after 20 weeks of pregnancy.

  • Who Can Receive the Non-mRNA COVID-19 Vaccine Now?

    The FDA recently limited the use of the Janssen COVID-19 vaccine.

  • Prevalence of Acute Myocarditis Related to COVID-19 Vaccination and SARS-CoV-2

    Acute myocarditis is a diagnosis that has had a significant rise in prevalence and is the center of many recent discussions in the medical literature. Much of this recent increase has been secondary to SARS-CoV-2 and the COVID-19 vaccines. Amid the global SARS-CoV-2 pandemic, acute myocarditis has become much more prevalent in patients where it was previously a rare pathology. As a result of this outbreak, it has become a disease entity necessitating new and ever evolving clinical guidelines.

  • Herpes Vaccine Could Be Available by 2030

    Early efforts to produce a protein-based vaccine for herpes failed. But a new mRNA approach has outperformed the efficacy of the past vaccines in preclinical trials and is expected to be introduced in clinical trials in the second half of 2022, investigators say. This new approach for a prophylactic genital herpes vaccine showed great promise in early studies.

  • COVID-19 Vaccine mRNA Injection (Comirnaty)

    Comirnaty is the first COVID-19 vaccine to receive full FDA approval.

  • Proteomics: A New Method to Understand the Influence of Genetic Variation on Disease Pathogenesis

    The combination of genome-wide association studies with the analysis of messenger ribonucleic acid and unique proteins in the brain, cerebrospinal fluid, and plasma can shed new light on our understanding of the genetic risks for the development of various neurological diseases.

  • COVID-19 Vaccination: The Heart of the Matter

    The occurrence of myocarditis after receipt of COVID-19 mRNA vaccines is most frequent in young males and generally is benign, with rapid resolution with only supportive care. Careful analysis indicates that the benefit of vaccination outweighs the risk in all groups for whom the vaccine is recommended — including young males.
  • Moderna, Pfizer Vaccines Showing Strong Protection in Healthcare Personnel

    Preliminary results from an ongoing multisite case-control study of healthcare personnel in 25 states indicate the two mRNA COVID-19 vaccines are 94% effective in real-world conditions involving work and the community, the CDC reported. The study is underway at 33 sites, with 75% of enrolled healthcare workers employed at acute care hospitals.
  • Prominent Pastor, Scientists, Researchers Seek to Ease Vaccine Fears in Minority Populations

    Minority populations are more likely to participate in clinical research activities when they are encouraged by trusted authority figures, such as family physicians or pastors. One such pastor and author, Bishop T.D. Jakes of The Potter’s House in Dallas, decided to use his popular YouTube channel to broadcast information about the COVID-19 vaccine to dispel myths and to encourage his followers to take the shots.

  • CDC: Immune-Compromised Can Be Vaccinated for COVID-19

    Adults of any age with “certain underlying medical conditions are at increased risk for severe illness from the virus that causes COVID-19” and can be immunized with the approved mRNA COVID-19 vaccine “provided they have not had a severe allergic reaction to any of the ingredients in the vaccine,” the Centers for Disease Control and Prevention reports.